News

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The platform has the capability to reduce

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the opening of another RightSource^SM facility, and first in the United Kingdom, which will provide services to the

PINC AI^™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 100 top hospitals. The full list of recognized hospitals was published in an exclusive

Charles River Laboratories International, Inc. (NYSE: CRL) announced that it will host a virtual Meeting with Management on Thursday, September 21^st, beginning at 8:30 a.m. ET.

This virtual

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the

Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply L

Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-enabled healthcare improvement company, today announced three executive promotions that strategically position the

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:

• 
  Morgan Stanley 21^st Annual Global Healthcare

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9

Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest SAS, a leader in the development and provision of next-generation sequencing (NGS) testing services for biopharmaceuticals

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 2023 Wells Fargo Healthcare Conference, September 6 - 8, 2023, in Boston.

In connection

Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic

Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief

Charles River Laboratories International, Inc. (NYSE: CRL), today announced a High Quality (HQ) plasmid manufacturing collaboration with Fondazione Telethon. The rare disease organization will

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 fourth quarter and full year ended June 30, 2023

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2023. For the quarter, revenue was $1.06 billion, an increase of 8.9% from $973.1

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 40-cents per share on the Company’s capital stock, payable on September 5, 2023

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today

Charles River Laboratories International, Inc. (NYSE: CRL) announced the planned openings of Charles River Accelerator and Development Lab (CRADL®) locations in Seattle and Philadelphia, expanding

Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2023.

Second Quarter and Recent Highlights

• 
  Revenue totaled